Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central anxious process, conolidine modulates alternate molecular targets. A Science Innovations review identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide avail... https://josephu085brf0.madmouseblog.com/profile